Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

A Hypoxia-Inducible HIF1-GAL3ST1-Sulfatide Axis Enhances ccRCC Immune Evasion via Increased Tumor Cell-Platelet Binding.

Robinson CM, Poon BPK, Kano Y, Pluthero FG, Kahr WHA, Ohh M.

Mol Cancer Res. 2019 Aug 19. doi: 10.1158/1541-7786.MCR-19-0461. [Epub ahead of print]

PMID:
31427440
2.

Recent advances in inherited platelet disorders.

Pluthero FG, Kahr WHA.

Curr Opin Hematol. 2019 Sep;26(5):313-319. doi: 10.1097/MOH.0000000000000525.

PMID:
31348050
3.

Abnormal fibrinolysis recognized by thromboelastography in a case of severe bleeding with normal coagulation and platelet function, leads to detection of a novel SERPINF2 variant causing severe alpha-2-antiplasmin deficiency.

Egan G, Pluthero FG, Bouskill V, Hilliard P, Drury LJ, Carcao MD, Kahr WHA.

Br J Haematol. 2019 Sep;186(6):e198-e201. doi: 10.1111/bjh.16077. Epub 2019 Jul 8. No abstract available.

PMID:
31282989
4.

NBEAL2 (Neurobeachin-Like 2) Is Required for Retention of Cargo Proteins by α-Granules During Their Production by Megakaryocytes.

Lo RW, Li L, Leung R, Pluthero FG, Kahr WHA.

Arterioscler Thromb Vasc Biol. 2018 Oct;38(10):2435-2447. doi: 10.1161/ATVBAHA.118.311270.

PMID:
30354215
5.

Imaging Platelets and Megakaryocytes by High-Resolution Laser Fluorescence Microscopy.

Pluthero FG, Kahr WHA.

Methods Mol Biol. 2018;1812:13-31. doi: 10.1007/978-1-4939-8585-2_2.

PMID:
30171570
6.

NBEAL2 mutations and bleeding in patients with gray platelet syndrome.

Pluthero FG, Di Paola J, Carcao MD, Kahr WHA.

Platelets. 2018 Sep;29(6):632-635. doi: 10.1080/09537104.2018.1478405. Epub 2018 Jun 5. Review.

PMID:
29869935
7.

The Birth and Death of Platelets in Health and Disease.

Pluthero FG, Kahr WHA.

Physiology (Bethesda). 2018 May 1;33(3):225-234. doi: 10.1152/physiol.00005.2018. Review.

8.

Relative antibacterial functions of complement and NETs: NETs trap and complement effectively kills bacteria.

Azzouz L, Cherry A, Riedl M, Khan M, Pluthero FG, Kahr WHA, Palaniyar N, Licht C.

Mol Immunol. 2018 May;97:71-81. doi: 10.1016/j.molimm.2018.02.019. Epub 2018 Mar 20.

PMID:
29571059
9.

Balancing the yin and yang of SINE.

Pluthero FG, Kahr WHA.

Blood. 2017 Aug 31;130(9):1077-1078. doi: 10.1182/blood-2017-07-793398. No abstract available.

PMID:
28860324
10.

Discrepant platelet and plasma von Willebrand factor in von Willebrand disease patients with p.Pro2808Leufs*24.

Bowman ML, Pluthero FG, Tuttle A, Casey L, Li L, Christensen H, Robinson KS, Lillicrap D, Kahr WHA, James P.

J Thromb Haemost. 2017 Jul;15(7):1403-1411. doi: 10.1111/jth.13722. Epub 2017 Jun 6.

11.

Loss of the Arp2/3 complex component ARPC1B causes platelet abnormalities and predisposes to inflammatory disease.

Kahr WH, Pluthero FG, Elkadri A, Warner N, Drobac M, Chen CH, Lo RW, Li L, Li R, Li Q, Thoeni C, Pan J, Leung G, Lara-Corrales I, Murchie R, Cutz E, Laxer RM, Upton J, Roifman CM, Yeung RS, Brumell JH, Muise AM.

Nat Commun. 2017 Apr 3;8:14816. doi: 10.1038/ncomms14816.

12.

α-granule biogenesis: from disease to discovery.

Chen CH, Lo RW, Urban D, Pluthero FG, Kahr WH.

Platelets. 2017 Mar;28(2):147-154. doi: 10.1080/09537104.2017.1280599. Epub 2017 Feb 22. Review.

PMID:
28277061
13.

Decreased numbers of dense granules in fetal and neonatal platelets.

Urban D, Pluthero FG, Christensen H, Baidya S, Rand ML, Das A, Shah PS, Chitayat D, Blanchette VS, Kahr WH.

Haematologica. 2017 Feb;102(2):e36-e38. doi: 10.3324/haematol.2016.152421. Epub 2016 Nov 3. No abstract available.

14.

Complement Activation Induces Neutrophil Adhesion and Neutrophil-Platelet Aggregate Formation on Vascular Endothelial Cells.

Riedl M, Noone DG, Khan MA, Pluthero FG, Kahr WHA, Palaniyar N, Licht C.

Kidney Int Rep. 2016 Aug 31;2(1):66-75. doi: 10.1016/j.ekir.2016.08.015. eCollection 2017 Jan.

15.

Von Willebrand factor regulates complement on endothelial cells.

Noone DG, Riedl M, Pluthero FG, Bowman ML, Liszewski MK, Lu L, Quan Y, Balgobin S, Schneppenheim R, Schneppenheim S, Budde U, James P, Atkinson JP, Palaniyar N, Kahr WH, Licht C.

Kidney Int. 2016 Jul;90(1):123-34. doi: 10.1016/j.kint.2016.03.023. Epub 2016 May 25.

16.

NETosing Neutrophils Activate Complement Both on Their Own NETs and Bacteria via Alternative and Non-alternative Pathways.

Yuen J, Pluthero FG, Douda DN, Riedl M, Cherry A, Ulanova M, Kahr WH, Palaniyar N, Licht C.

Front Immunol. 2016 Apr 14;7:137. doi: 10.3389/fimmu.2016.00137. eCollection 2016.

17.

Intracellular Trafficking, Localization, and Mobilization of Platelet-Borne Thiol Isomerases.

Crescente M, Pluthero FG, Li L, Lo RW, Walsh TG, Schenk MP, Holbrook LM, Louriero S, Ali MS, Vaiyapuri S, Falet H, Jones IM, Poole AW, Kahr WH, Gibbins JM.

Arterioscler Thromb Vasc Biol. 2016 Jun;36(6):1164-73. doi: 10.1161/ATVBAHA.116.307461. Epub 2016 Apr 14.

18.

Impact of aerobic exercise on haemostatic indices in paediatric patients with haemophilia.

Kumar R, Bouskill V, Schneiderman JE, Pluthero FG, Kahr WH, Craik A, Clark D, Whitney K, Zhang C, Rand ML, Carcao M.

Thromb Haemost. 2016 Jun 2;115(6):1120-8. doi: 10.1160/TH15-09-0757. Epub 2016 Feb 25.

PMID:
26917411
19.

Platelet production: new players in the field.

Pluthero FG, Kahr WH.

Blood. 2016 Feb 18;127(7):797-9. doi: 10.1182/blood-2016-01-687707. No abstract available.

PMID:
26893396
20.

Non-genomic activities of retinoic acid receptor alpha control actin cytoskeletal events in human platelets.

Rondina MT, Freitag M, Pluthero FG, Kahr WH, Rowley JW, Kraiss LW, Franks Z, Zimmerman GA, Weyrich AS, Schwertz H.

J Thromb Haemost. 2016 May;14(5):1082-94. doi: 10.1111/jth.13281. Epub 2016 Mar 22.

21.

FlnA binding to PACSIN2 F-BAR domain regulates membrane tubulation in megakaryocytes and platelets.

Begonja AJ, Pluthero FG, Suphamungmee W, Giannini S, Christensen H, Leung R, Lo RW, Nakamura F, Lehman W, Plomann M, Hoffmeister KM, Kahr WH, Hartwig JH, Falet H.

Blood. 2015 Jul 2;126(1):80-8. doi: 10.1182/blood-2014-07-587600. Epub 2015 Apr 2.

22.

Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia.

Noetzli L, Lo RW, Lee-Sherick AB, Callaghan M, Noris P, Savoia A, Rajpurkar M, Jones K, Gowan K, Balduini C, Pecci A, Gnan C, De Rocco D, Doubek M, Li L, Lu L, Leung R, Landolt-Marticorena C, Hunger S, Heller P, Gutierrez-Hartmann A, Xiayuan L, Pluthero FG, Rowley JW, Weyrich AS, Kahr WHA, Porter CC, Di Paola J.

Nat Genet. 2015 May;47(5):535-538. doi: 10.1038/ng.3253. Epub 2015 Mar 25.

23.

Dynamin 2-dependent endocytosis is required for normal megakaryocyte development in mice.

Bender M, Giannini S, Grozovsky R, Jönsson T, Christensen H, Pluthero FG, Ko A, Mullally A, Kahr WH, Hoffmeister KM, Falet H.

Blood. 2015 Feb 5;125(6):1014-24. doi: 10.1182/blood-2014-07-587857. Epub 2014 Dec 2.

24.

Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.

Jodele S, Fukuda T, Vinks A, Mizuno K, Laskin BL, Goebel J, Dixon BP, Teusink A, Pluthero FG, Lu L, Licht C, Davies SM.

Biol Blood Marrow Transplant. 2014 Apr;20(4):518-25. doi: 10.1016/j.bbmt.2013.12.565. Epub 2013 Dec 25.

25.

Successful treatment of DEAP-HUS with eculizumab.

Noone D, Waters A, Pluthero FG, Geary DF, Kirschfink M, Zipfel PF, Licht C.

Pediatr Nephrol. 2014 May;29(5):841-51. doi: 10.1007/s00467-013-2654-x. Epub 2013 Nov 20.

PMID:
24249282
26.

Identification of a rare coding variant in complement 3 associated with age-related macular degeneration.

Zhan X, Larson DE, Wang C, Koboldt DC, Sergeev YV, Fulton RS, Fulton LL, Fronick CC, Branham KE, Bragg-Gresham J, Jun G, Hu Y, Kang HM, Liu D, Othman M, Brooks M, Ratnapriya R, Boleda A, Grassmann F, von Strachwitz C, Olson LM, Buitendijk GH, Hofman A, van Duijn CM, Cipriani V, Moore AT, Shahid H, Jiang Y, Conley YP, Morgan DJ, Kim IK, Johnson MP, Cantsilieris S, Richardson AJ, Guymer RH, Luo H, Ouyang H, Licht C, Pluthero FG, Zhang MM, Zhang K, Baird PN, Blangero J, Klein ML, Farrer LA, DeAngelis MM, Weeks DE, Gorin MB, Yates JR, Klaver CC, Pericak-Vance MA, Haines JL, Weber BH, Wilson RK, Heckenlively JR, Chew EY, Stambolian D, Mardis ER, Swaroop A, Abecasis GR.

Nat Genet. 2013 Nov;45(11):1375-9. doi: 10.1038/ng.2758. Epub 2013 Sep 15.

27.

Abnormal megakaryocyte development and platelet function in Nbeal2(-/-) mice.

Kahr WH, Lo RW, Li L, Pluthero FG, Christensen H, Ni R, Vaezzadeh N, Hawkins CE, Weyrich AS, Di Paola J, Landolt-Marticorena C, Gross PL.

Blood. 2013 Nov 7;122(19):3349-58. doi: 10.1182/blood-2013-04-499491. Epub 2013 Jul 16.

28.

Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy.

Jodele S, Licht C, Goebel J, Dixon BP, Zhang K, Sivakumaran TA, Davies SM, Pluthero FG, Lu L, Laskin BL.

Blood. 2013 Sep 19;122(12):2003-7. doi: 10.1182/blood-2013-05-501445. Epub 2013 Jun 27.

29.

Monitoring and modeling treatment of atypical hemolytic uremic syndrome.

Heinen S, Pluthero FG, van Eimeren VF, Quaggin SE, Licht C.

Mol Immunol. 2013 May;54(1):84-8. doi: 10.1016/j.molimm.2012.10.044. Epub 2012 Dec 3.

PMID:
23220071
30.

The VPS33B-binding protein VPS16B is required in megakaryocyte and platelet α-granule biogenesis.

Urban D, Li L, Christensen H, Pluthero FG, Chen SZ, Puhacz M, Garg PM, Lanka KK, Cummings JJ, Kramer H, Wasmuth JD, Parkinson J, Kahr WH.

Blood. 2012 Dec 13;120(25):5032-40. doi: 10.1182/blood-2012-05-431205. Epub 2012 Sep 21.

31.

The cell motility modulator Slit2 is a potent inhibitor of platelet function.

Patel S, Huang YW, Reheman A, Pluthero FG, Chaturvedi S, Mukovozov IM, Tole S, Liu GY, Li L, Durocher Y, Ni H, Kahr WH, Robinson LA.

Circulation. 2012 Sep 11;126(11):1385-95. doi: 10.1161/CIRCULATIONAHA.112.105452. Epub 2012 Aug 3.

PMID:
22865890
32.

Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab.

Noone D, Al-Matrafi J, Tinckam K, Zipfel PF, Herzenberg AM, Thorner PS, Pluthero FG, Kahr WH, Filler G, Hebert D, Harvey E, Licht C.

Am J Transplant. 2012 Sep;12(9):2546-53. doi: 10.1111/j.1600-6143.2012.04124.x. Epub 2012 Jun 8.

33.

Diannexin, an annexin A5 homodimer, binds phosphatidylserine with high affinity and is a potent inhibitor of platelet-mediated events during thrombus formation.

Rand ML, Wang H, Pluthero FG, Stafford AR, Ni R, Vaezzadeh N, Allison AC, Kahr WH, Weitz JI, Gross PL.

J Thromb Haemost. 2012 Jun;10(6):1109-19. doi: 10.1111/j.1538-7836.2012.04716.x.

34.

Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndrome.

Kahr WH, Hinckley J, Li L, Schwertz H, Christensen H, Rowley JW, Pluthero FG, Urban D, Fabbro S, Nixon B, Gadzinski R, Storck M, Wang K, Ryu GY, Jobe SM, Schutte BC, Moseley J, Loughran NB, Parkinson J, Weyrich AS, Di Paola J.

Nat Genet. 2011 Jul 17;43(8):738-40. doi: 10.1038/ng.884.

35.

Decreased in vitro thrombin generation and clot stability in human FXII-null blood and plasma.

Pluthero FG, Ryan C, Williams S, Brandão LR, Kahr WH.

Br J Haematol. 2011 Jan;152(1):111-2. doi: 10.1111/j.1365-2141.2010.08382.x. Epub 2010 Sep 29. No abstract available.

PMID:
20880114
36.

Megakaryocyte and platelet abnormalities in a patient with a W33C mutation in the conserved SH3-like domain of myosin heavy chain IIA.

Kahr WH, Savoia A, Pluthero FG, Li L, Christensen H, De Rocco D, Traivaree C, Butchart SE, Curtin J, Stollar EJ, Forman-Kay JD, Blanchette VS.

Thromb Haemost. 2009 Dec;102(6):1241-50. doi: 10.1160/TH09-02-0119.

PMID:
19967157
37.

Platelet-associated complement factor H in healthy persons and patients with atypical HUS.

Licht C, Pluthero FG, Li L, Christensen H, Habbig S, Hoppe B, Geary DF, Zipfel PF, Kahr WH.

Blood. 2009 Nov 12;114(20):4538-45. doi: 10.1182/blood-2009-03-205096. Epub 2009 Aug 24.

PMID:
19704120
38.

Abnormalities in villin gene expression and canalicular microvillus structure in progressive cholestatic liver disease of childhood.

Phillips MJ, Azuma T, Meredith SL, Squire JA, Ackerley CA, Pluthero FG, Roberts EA, Superina RA, Levy GA, Marsden PA.

Lancet. 2003 Oct 4;362(9390):1112-9.

PMID:
14550699
39.

Rapid purification of high-activity Taq DNA polymerase.

Pluthero FG.

Nucleic Acids Res. 1993 Oct 11;21(20):4850-1. No abstract available.

40.

Superoxide dismutase halts cycling of murine erythroid progenitor cells prior to S phase in vitro and possibly in vivo.

Pluthero FG, van der Gaag H, Eskinazi D.

Int J Hematol. 1991 Oct;54(5):357-62.

PMID:
1756246
41.

Superoxide dismutase as an inhibitor of erythroid progenitor cell cycling.

Pluthero FG, Axelrad AA.

Ann N Y Acad Sci. 1991;628:222-32. Review.

PMID:
2069305
42.

Superoxide dismutase specifically inhibits erythroid cell DNA synthesis and proliferation.

Pluthero FG, Shreeve M, Eskinazi D, Van der Gaag H, Axelrad A.

Growth Factors. 1991;4(4):297-304.

PMID:
1764266
43.
44.

A protein (NRP) that negatively regulates erythroid stem cell proliferation: antagonism to IL-3 stimulation.

Axelrad AA, Shreeve MM, Eskinazi D, Pluthero FG.

Prog Clin Biol Res. 1990;352:79-86. No abstract available.

PMID:
2205877
46.

Genetic differences in malathion avoidance and resistance in Drosophila melanogaster.

Pluthero FG, Threlkeld SF.

J Econ Entomol. 1981 Dec;74(6):736-40. No abstract available.

PMID:
6799555
47.

Some aspects of maze behavior in Drosophila melanogaster.

Pluthero FG, Threlkeld SF.

Behav Neural Biol. 1979 Jun;26(2):254-7. No abstract available.

PMID:
115456

Supplemental Content

Loading ...
Support Center